Connect Biopharma Holdings Limited (NASDAQ:CNTB) reported mixed preliminary results on September 15 from its Phase 2 Seabreeze STAT asthma study. Rademikibart produced a numerical 66% reduction in treatment failure over 28 days versus placebo, but the primary endpoint missed statistical significance, with p=0.153.
Connect Biopharma Holdings Limited also reported a lung-function benefit on a prespecified secondary endpoint (p=0.023). The release did not disclose whether the analysis controlled for multiple comparisons, so the finding warrants confirmation following the primary-endpoint miss.
The randomized, double-blind study enrolled 160 adults and adolescents experiencing an acute asthma exacerbation with type 2 inflammation. Participants received a single subcutaneous dose of rademikibart or placebo alongside standard care.
Bull Case
The lung-function result gives Connect Biopharma Holdings Limited a measurable basis for further development. At Day 7, post-bronchodilator forced expiratory volume in one second, or FEV1, improved by 250 mL with rademikibart versus 120 mL with placebo. The difference was 130 mL.
FEV1 measures how much air a person can forcefully exhale in one second. Here, testing occurred after administration of a bronchodilator, a medicine that opens the airways.
Management proposes using this Day 7 measure as the primary endpoint in Phase 3. Prespecification makes the finding useful for planning, but does not establish confirmatory significance after the primary-endpoint miss.
Connect Biopharma Holdings Limited also reported no new safety signals during the study. There were no adverse events leading to discontinuation, with one serious adverse event in the rademikibart group and three in the placebo group. Larger studies will provide a more complete safety assessment.
Bear Case
The primary endpoint remains the central limitation. Treatment failure included death, asthma hospitalization, emergency or unscheduled visits for worsening symptoms, or intensified drug treatment within 28 days. The study did not establish a statistically significant reduction in that composite outcome.
Connect Biopharma Holdings Limited attributed the miss to fewer treatment failures than expected. That explanation may inform future sample-size calculations, but the numerical 66% reduction remains uncertain. Improved lung function alone does not demonstrate fewer hospital visits or treatment escalations.
The proposed Phase 3 endpoint also remains a company plan. FDA agreement on the endpoint, population, and overall development program has not been announced. Management expects results from the separate chronic obstructive pulmonary disease, or COPD, study later in September before seeking alignment with the agency.
Development costs add financial pressure. Connect Biopharma Holdings Limited held $31.5 million in cash, cash equivalents and short-term investments as of June 30. Second-quarter research and development expense rose to $16.3 million from $8.8 million, while net loss widened to $17.3 million from $12.9 million.
In its August 12 release, management projected sufficient funding for at least one year from that release under its operating plan. A longer or larger pivotal program could require additional capital or partnership funding.
Hedge Fund Sentiment
The filings available so far reflect positions held before Connect Biopharma Holdings Limited reported the Seabreeze STAT asthma results. Insider Monkey’s database showed 14 hedge funds holding Connect Biopharma Holdings Limited at the end of 2Q2026, down from 17 funds three months earlier.
Conclusion
Connect Biopharma Holdings Limited has a plausible development path supported by the lung-function finding. FDA feedback, the final pivotal design, and funding requirements will determine whether that signal can become a viable Phase 3 program.
READ NEXT: CBRE Group (CBRE) Unit Buys $1.6 Billion Net-Lease Platform. Can Scale Lift Fee Earnings? and Mastercard (MA) Partners With Flowcart. Can In-Chat Payments Deliver Profitable Growth?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center